Dr. Ansell Discusses Immune Evasion in Lymphoma

Video

In Partnership With:

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Ansell says that one of the biggest challenges in lymphoma is that many immune cells are present in the tumor, but they are not killing the tumor cells. This begs the question of how the tumor cell hides from the immune system as well as it does. There are many barriers to a good response in lymphoma, Ansell says. The immune cells are worn out from being persistently activated, and sometimes there are other cells in the area that can suppress their activity.

There are proteins that either are made on the tumor cell, or proteins like cytokines that activate the immune system, that exhaust the immune system over time. Ansell says the goal in answering this question of immune evasion is getting the T cell to kill the tumor cell efficiently. There are multiple strategies under evaluation to try to reach this goal.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Annie Im, MD, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology